Use of 111In-pentetreotide scintigraphy for diagnosis and management of resistant macroprolactinoma

Endocrine. 2018 Jun;60(3):532-534. doi: 10.1007/s12020-017-1486-z. Epub 2017 Dec 6.

Authors

V Del Gatto¹, C Bima¹, S Chiloiro², A Giampietro¹, A Bianchi¹

Affiliations

¹ Pituitary Unit, Gemelli Hospital Foundation, Catholic University, Rome, Italy.
² Pituitary Unit, Gemelli Hospital Foundation, Catholic University, Rome, Italy. schiloiro@gmail.com.

PMID: 29214441
DOI: 10.1007/s12020-017-1486-z

No abstract available

Publication types

Case Reports

MeSH terms

Aged, 80 and over
Dopamine Agonists / therapeutic use
Humans
Indium Radioisotopes
Male
Pituitary Neoplasms / diagnostic imaging*
Pituitary Neoplasms / drug therapy
Prolactinoma / diagnostic imaging*
Prolactinoma / drug therapy
Radionuclide Imaging / methods*

Substances

Dopamine Agonists
Indium Radioisotopes
Indium-111